Prophylactic central neck dissection in differentiated thyroid cancer: A procedure in search of an indication

Thyroid

Volumn 22, Issue 4, 2012, Pages 341-343

  Cooper, David S ^a   Tufano, Ralph P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NECK DISSECTION; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; HUMAN; LYMPH NODE METASTASIS; NECK DISSECTION; PRIORITY JOURNAL; REOPERATION; REVIEW; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION;

FEMALE; HUMANS; MALE; NECK; THYROID NEOPLASMS;

EID: 84859475263     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.2204.ed     Document Type: Review

References (21)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM; American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
3. Sosa JA, Udelsman R 2006 Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol 94:701-707. (Pubitemid 44902069)
4. Chisholm EJ, Kulinskaya E, Tolley NS 2009 Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 119:1135-1139.
5. Rotstein L 2009 The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 99:186-188.
6. Carty SE,CooperDS, DohertyGM, DuhQY, KloosRT,Mandel SJ, Randolph GW, Stack BC Jr, Steward DL, Terris DJ, Thompson GB, Tufano RP, Tuttle RM, Udelsman R 2009 Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 19:1153-1158.
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
8. Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, Rodari M, Chiti A, Beck-Peccoz P, Fugazzola L 2009 Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers or = 2 cm. Endocr Relat Cancer 16:201-210.
9. Moo TA, McGill J, Allendorf J, Lee J, Fahey T 3rd, Zarnegar R 2010 Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma. World J Surg 34:1187-1191.
10. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, Fahey TJ 3rd, Zarnegar R 2010 Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: A meta-analysis. Ann Surg Oncol 17:3287-3293.
11. Monchik JM, Simon CJ, Caragacianu DL, Thomay AA, Tsai V, Cohen J, Mazzaglia PJ 2009 Does failure to perform prophylactic level VI node dissection leave persistent disease detectable by ultrasonography in patients with low-risk papillary carcinoma of the thyroid? Surgery 146 1182-1187.
12. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM 2010 Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 148:1100-1106.
13. Carling T,Carty SE,CiarleglioMM,CooperDS,Doherty G, Kim LT, Kloos RT, Mazzaferri E, Peduzzi PN, Roman S, Sippel RS, Sosa JA, Stack BC, StewardD, Tufano RP, Tuttle RM, Udelsman R 2011American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 22:237-244.
14. National Institutes of Health. Prophylactic central lymph node dissection in papillary thyroid microcarcinoma. Available at http://clinicaltrials.gov/ct 2/show/NCT00795782? term= Prophylactic + central + lymph + node + dissection + in + papillary + thyroid + microcarcinoma&rank = 1 (accessed January 29, 2012).
15. Moreno MA, Edeikin-Monroe BS, Siegel ER, Sherman SI, Clayman GL 2012 In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 22:347-355.
16. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, Chami L, Schlumberger M, Travagli JP 2009 Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab 94: 1162-1167.
17. Randolph GW, Duh Q-Y, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM. The prognostic significance of nodal metastases from papillary thyroid cancer can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension: report of the ATA Surgical Affairs Committee. Thyroid (submitted for publication).
18. Teixeira G, Teixeira T, Gubert F, Chikota H, Tufano RP 2011 The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery 150:1161-1167.
19. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment a systematic review and metaanalysis. Medicine (in press).
20. Tufano RP, Bishop J, Wu G. The association between the BRAF mutation status and the clinicopathologic characteristics and outcomes of patients with recurrent/persistent papillary thyroid cancer in the central neck that have undergone re-operative central compartment dissection. Laryngoscope (submitted for publication).
21. O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS 2010 BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148: 1139-1145.